McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
The biblical character who goes ‘down the rabbit hole’ into an alternate reality − just like Alice in Wonderland 
What should you do if you can’t pay your rent or mortgage? 
Some experts say the US economy is on the up, but here’s why voters don’t think so 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
High interest rates aren’t going away anytime soon – a business economist explains why 
Water cremation: sustainable body disposal is coming to Scotland – here are the benefits 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
Doing a job you find meaningful is great – until it consumes your life 
Supporting ‘democracy’ is hard for many who feel government and the economy are failing them 
BioNTech SE, a Mainz-based German biotech firm, confronts a homegrown lawsuit seeking compensation for purported COVID-19 vaccine side effects. The initial case, scheduled for court on June 12, is expected to precipitate nationwide litigation.
BioNTech is set to attend the first court hearing on Monday, June 12. It will go to court to defend itself from the first case filed by a German woman who allegedly suffered from side effects after receiving her COVID-19 jab. She is seeking damages, and more cases are expected to be filed across the country after this.
According to Reuters, the plaintiff is suing the biotech firm and asking for at least €150,000 or about $161,500 in damages. The regional court in Hamburg said that in her lawsuit, the woman said the amount is for bodily harm and other material damages that were not specified.
For this case, she is being represented by Rogert & Ulbrich law firm. She claimed that after the jab, she suffered from pains in the upper part of her body, developed a sleeping disorder, fatigue, and swollen extremities. Her lawyer, Tobias Ulbrich, told the publication that will challenge the assessment made by European Union regulators and the vaccine assessment bodies in Germany that said the BioNTech vaccine has positive benefits.
In any case, it was mentioned that under German pharmaceutical law, drug or vaccine makers are only liable to give compensation for side effects if medical science shows that their products bear incorrect information or have caused disproportionate harm commensurate to their benefits.
With this, BioNTech believes that after a careful review and consideration of the case, it concluded that the lawsuit holds no merit. It also noted that the same vaccine was already received by some 1.5 billion people around the world, including more than 64 million Germans.
Meanwhile, despite BioNTech’s statements, Financial Times reported that the law firm representing the woman insisted that the burden of proof and the possible compensation is lower in Germany. Thus, it is confident that their case against BioNTech is strong.
Photo: Mat Napo/Unsplash
